What gets paid for!? I remember having a HER2 3+ gastric cancer guy about 12 years ago. Got all better on Herceptin, but after 20 months there was progression. Couldn't get a second line therapy paid for. How do you do it? (Couldn't get free drug either). (@davideyoungmd)

#Tucatinib + #Trastuzumab was approved earlier this year for refractory mCRC HER 2 positive disease. Previously, we had also discussed the implications of anti-egfr therapy w/ @GIcancerDoc and @CathyEngMD in this subset + RAS WT. This study by @GIcancerDoc continues to support:… https://t.co/16FDqtJdMS (@OncBrothers)

But sir you will be astonished that in a country like Pakistan , people do not have access to Rituximab even in DLBCL...herceptin/Perjecta in Breast cancer,Others talking of polatuzuma,even for PFS benefits only....Do these patients have no rights to access to quality drugs? (@DrManzoorKhan1)

Getting closer to another potential targeted therapy in lung cancer: ( and potential tumor agnostic therapy)👇🏽 #Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC Based on PhI/II data ORR 35% #lcsm https://t.co/w0g6EH8y56 via @onclive (@Latinamd)

Getting closer to another potential targeted therapy in lung cancer: ( and potential tumor agnostic therapy)👇🏽 #Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC Based on PhI/II data ORR 35% #lcsm https://t.co/w0g6EH8y56 via @onclive (@Latinamd)

Getting closer to another potential targeted therapy in lung cancer: ( and potential tumor agnostic therapy)👇🏽 #Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC Based on PhI/II data ORR 35% #lcsm https://t.co/w0g6EH8y56 via @onclive (@Latinamd)

Getting closer to another potential targeted therapy in lung cancer: ( and potential tumor agnostic therapy)👇🏽 #Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC Based on PhI/II data ORR 35% #lcsm https://t.co/w0g6EH8y56 via @onclive (@Latinamd)

Getting closer to another potential targeted therapy in lung cancer: ( and potential tumor agnostic therapy)👇🏽 #Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC Based on PhI/II data ORR 35% #lcsm https://t.co/w0g6EH8y56 via @onclive (@Latinamd)

Getting closer to another potential targeted therapy in lung cancer: ( and potential tumor agnostic therapy)👇🏽 #Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC Based on PhI/II data ORR 35% #lcsm https://t.co/w0g6EH8y56 via @onclive (@Latinamd)

Patient with metastatic cholangiosarcoma with mRNA+ her2 (ihc, DNA NA) 24+ ongoing months PR on lapatinib/trastuzumab ⁦@AaronGoodman33⁩ ⁦⁦@BostonGenomics⁩ See Akram at al. JCO PO July 2023. Impressive response predicted by Her2 mRNA (@Dr_R_Kurzrock)

Updates to the @ASCO Living Guidelines on Therapy for Stage IV NSCLC with Driver Alterations now @JCO_ASCO. Additions include amivantamab and mobocertinib for #EGFR exon 20 insertion NSCLC and sotorasib for #KRAS G12C NSCLC. https://t.co/NdWku4z9BU (@StephenVLiu)

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: @ASCO Living Guideline 📌Added update on amivantamab, mobocertinib and sotorasib @JCO_ASCO @OncoAlert https://t.co/VK0ojQpfeM (@dr_yakupergun)

Zipalertinib in Lung Cancer Harboring EGFR Exon 20 Insertions https://t.co/ogKdpiWqFm. Responses seen from starting till the final dose level. Another agent apart from Amivatinab, poziotinib and mobocertinib @JCO_ASCO @LungConnectIN (@DrVijayPatil11)

In this #ASCO23 interview, @DrShubhamPant of @MDAndersonNews discusses the results of the #HERIZON-BTC-01 trial of #zanidatamab in previously treated #HER2-amplified #biliary tract #cancers. Listen to the conversation here! https://t.co/9j8Xvm7ds3 (@OncData)

Results from the MOUNTAINEER trial show a clinically meaningful antitumor activity and favorable tolerability for tucatinib plus trastuzumab in metastatic colorectal cancer https://t.co/xjxSFJIir4 #fondazionebonadonna #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)

Excited to share the results of the MIMOSA-trial, in which we evaluated the novel combination of monalizumab & trastuzumab for HER2+ MBC! Thanks to the entire MIMOSA-team! @lab_kok https://t.co/WwufyrM0vG (@VeerleGeurts)

Targeting the HER2 Pathway in GI Cancers at #WCGIC2023 👉Amazing evolutions of targeted therapies for Her2+ tumors 👉T-DXt with pan-tumor activity 👉T + Tucatinib & Zanidatimab very promising 👉We need to better understand the iTME for IO combinations @myESMO @OncoAlert @WCGIC (@ArndtVogel)

#WCGIC2023 💊 Emerging 🎯 in #GI cancer 🪑Dr. Van Cutsem + Dr. Carnero 🗣️@ValeGambardella 🎯 HER2 ✔️ T-DxT for #GastricCancer #DestinyGastric01 2nd line #FDA --> ⏳#DestinyGastric02 ✔️Trastuzumab + tucatinib for #CCR #MOUNTAINEER ✔️Zanidatamab #BiliaryTract #HERIZONBTC01 @WCGIC (@DrMirallas)

Yes definitely using in carcinosarcoma. What about advanced serous HER2 positive? Thoughts about IO vs trastuzumab? (@LAMcAlarnenMD)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

34F, Rt multicenteric BCA, HER2 + TNBC. S/p ddAC+ T+H+P ->SM + SLN -> mpT1cN0. HER2 positive lesion not seen. How to select adjuvant Rx ? HERCEPTIN + capacitabine? @stolaney1 @IlanaSchlam @HemOncFellows @DFCI_BreastOnc (@Arif_Hameed)

Hot off the press from @ASCO #TAPUR Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study https://t.co/ilNcPYdV8U (@rschilsky)

Subcutaneous delivery of fixed-dose adjuvant pertuzumab + trastuzumab proved to have favorable tolerability, w/ a safety profile consistent with that seen with intravenous delivery of the regimen in pts w/ HER2+ breast cancer. @BCJoyceO #bcsm #oncology https://t.co/CmjDDZZyok (@OncLive)

11/21 #TumorBoardTuesday ✅In #cholangiocarcinoma @DrShubhamPant & Dr. Nakamura🗣️exciting data on HER2🎯💊 👉Tx w/ tucat+trastuz➡️a 47% ORR in 30 Pts & 👉Zanidatamab➡️a 41% ORR in 80 Pts ✅Giving us two new options for these patients that we might be able to use in sequence❓ (@MPishvaian)

Zanidatamab could potentially treat HER2 positive biliary tract cancer. "It's not a curative option for our patients, but it definitely does give them long-term disease control," says our Dr. Shubham Pant. https://t.co/85c5DhK7fL @HealthDayTweets @DrShubhamPant #EndCancer (@MDAndersonNews)

Subcutaneous delivery of fixed-dose adjuvant pertuzumab + trastuzumab proved to have favorable tolerability, w/ a safety profile consistent with that seen with intravenous delivery of the regimen in pts w/ HER2+ breast cancer. @BCJoyceO #bcsm #oncology https://t.co/zuHJlfdCLv (@OncLive)

Without level 1 evidence, I may squeeze in Neratinib/Cape between #Tdxd, and T-DM1 hoping to upregulate HER2 again (some data there), in case downregulation was the main mechanism of resistance to Tdxd. #bcsm #Her2 #metastaticbreastcacer (@AnisToumeh)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/hCLD2Q81YP (@OncLive)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/AI03UpN2Va (@OncLive)

Sunvozertinib EGFR exon20 ins inhibitor -ORR 60.8% across exon20ins subtypes -cORR 48.5% in pts with CNS mets -toxicity profile w/ high rates of diarrhea, rash, anemia #ASCO23 #LCSM @AnaVManana (@OncLive)

Amazing analysis by MD Riess at #ASCO23 about the first pivotal study that confirmed sunvozertinib is superior anti-tumor efficacy than the current available therapy for NSCLC with EGFR exon20ins 🙌 (@Dr_Ivanoncologo)

“These results support zanidatamab having meaningful clinical benefit and a potential as a future treatment option in HER2+ [#biliarytractcancers],” said @DrShubhamPant of @MDAndersonNews https://t.co/4dDkp0QXVq #ASCO23 @ASCO @ASCOPres (@OBRtweets)

this is fantastic data, and intriguing! maybe a clue for future Rx of #pancreaticcancer: Is there something about pancreatic cancer cells that inhibits HER2-triggered cell death pathways? #Her2 Thanks for this work, Dr. Funda Meric-Bernstam @MDAndersonNews #ASCO23 (@ESchattner)

Zanidatamab demonstrated antitumor activity, including rapid and durable responses in patients with treatment-refractory HER2-positive biliary tract cancer @DrShubhamPant (@VibhaJayaraj)

.@RutgersCancer’s Dr. Mridula George @MridulaGeorgeMD & colleagues present “A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.” at #ASCO23 @ASCO https://t.co/ICJ8QgjSsk #ASCODailyNews @RWJBarnabas @RWJMS (@RutgersCancer)

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer @DrShubhamPant @MDAndersonNews @ASCO #ASCO23 #oncology https://t.co/EGmjceI4ky (@OncLive)

Last oral abstract of the day (but not least!), @DrShubhamPant presenting @JazzPharma Zanidatamab in HER-2 + biliary tract cancer. #ASCO23 (@jonmizrahi)

🆕HERIZON-BTC-01 study: Zanidatamab in previously-treated 🎯#HER2‑amplified biliary tract cancer (BTC) @DrShubhamPant Again gallbladder ca >1/2 of these cases. #ASCO23 @OncoAlert HER2➕in cholangiocarcinoma needs approvals. @NCCN only trastuzumab/pertuzumab. No @FDAOncology. (@pashtoonkasi)

Tucatinib plus trastuzumab for previously treated metastatic BTC with Her2 positive. Median PFS of 5.5 months. @ASCO @agrothey @GIcancerDoc #ASCO23 (@SuyogCancer)

🔥 SGNTUC-019: Tucatinib & trastuzumab for HER2+ biliary tract cancer #ASCO23 🔎phs-II, 30 pts, Her2 overexpression/amplification 👉ORR: 46.7%, DoR 6.0mo, DCR 76.7% 👉mPFS 5.5 mo, 12-mo OS rate 53.8% ✅Supports TUC/Tras as CTx-free💊option @myESMO @OncoAlert @EASLedu @curecc… https://t.co/s4WLttkRA2 (@ArndtVogel)

🔥HERIZON-BTC-01: Zanidatamab in HER2‑amplified biliary tract cancer #ASCO23 🔎🌎phs-II, 87 pts 👉cORR 41%, DOR 12.9 mo 👉mPFS 5.5 👉no grade 4 TRAEs ✅Durable responses with manageable safety profile -> very promising 💊 option @myESMO @OncoAlert @EASLedu @curecc #livertwitter (@ArndtVogel)